Citadel Advisors
INMB icon

Citadel Advisors’s INmune Bio INMB Stock Holding History

Citadel Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Buy
+106,231
New +$147K ﹤0.01% 12221
2025
Q2 		– Sell
-101,511
Closed -$745K – 13744
2025
Q1 		$793K Buy
101,511
+49,314
+94% +$392K ﹤0.01% 7466
2024
Q4 		$244K Buy
52,197
+6,081
+13% +$31.7K ﹤0.01% 10085
2024
Q3 		$249K Buy
46,116
+15,426
+50% +$110K ﹤0.01% 9690
2024
Q2 		$271K Buy
30,690
+30,660
+102,200% +$302K ﹤0.01% 9339
2024
Q1 		$353 Sell
30
-33,821
-100% -$409K ﹤0.01% 14354
2023
Q4 		$381K Buy
33,851
+19,596
+137% +$164K ﹤0.01% 8669
2023
Q3 		$97.5K Sell
14,255
-25,585
-64% -$212K ﹤0.01% 10933
2023
Q2 		$362K Buy
39,840
+1,130
+3% +$9.08K ﹤0.01% 8644
2023
Q1 		$250K Sell
38,710
-3,316
-8% -$26.7K ﹤0.01% 9763
2022
Q4 		$266K Buy
42,026
+15,894
+61% +$113K ﹤0.01% 9569
2022
Q3 		$162K Buy
26,132
+9,469
+57% +$83.1K ﹤0.01% 10626
2022
Q2 		$147K Sell
16,663
-9,803
-37% -$73K ﹤0.01% 11005
2022
Q1 		$223K Sell
26,466
-41,427
-61% -$372K ﹤0.01% 11265
2021
Q4 		$693K Buy
67,893
+15,201
+29% +$225K ﹤0.01% 8868
2021
Q3 		$1.02M Sell
52,692
-3,364
-6% -$65K ﹤0.01% 8096
2021
Q2 		$985K Buy
+56,056
New +$755K ﹤0.01% 8406
2019
Q2 		– Sell
-10,191
Closed -$80K – 9500
2019
Q1 		$80K Buy
+10,191
New +$78.9K ﹤0.01% 8635

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's INMB Position: Q2 2026 in Review

Citadel Advisors opened a new position in INmune Bio (INMB) in Q2 2026: 106,231 shares worth $173K. The stake represents ﹤0.01% of the portfolio and ranks #12221 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INMB as recently as Q1 2025.

Citadel Advisors first reported a position in INMB in Q1 2019 and has held it in 18 quarters since. The position peaked at $1.02M in Q3 2021. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Citadel Advisors held 106,231 shares of INmune Bio worth $173K as of Q2 2026.
  • INmune Bio was a new Citadel Advisors position in Q2 2026.
  • INmune Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12221 holding.
  • Citadel Advisors first reported a position in INmune Bio in Q1 2019 and has held it in 18 quarters since.
  • Citadel Advisors's INmune Bio position peaked at $1.02M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.